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ABSTRACT
Younger patients with COVID-19 may experience an exaggerated immune response to SARS-CoV-2 infection and develop cytokine release 
syndrome (CRS), which may be life threatening. There is no proven antiviral therapy for COVID-19 so far, but profound immunosuppression 
has recently been suggested as a treatment for COVID-19-associated CRS. We present a case of life-threatening CRS caused by COVID-19 
infection with a favourable response to immunosuppressive therapy with tocilizumab (TCZ). The rapid clinical and biochemical improvement 
following TCZ administration suggests that treatment with immunotherapy can be life-saving in selected patients with COVID-19-induced 
CRS. 
LEARNING POINTS
• Cytokine release syndrome may cause sudden and potentially life-threatening clinical deterioration in COVID-19 pneumonia, particularly 
in younger patients.
• Immunosuppressive therapy may provide important additional therapeutic benefit in these patients.
• Tocilizumab, a specific IL-6 inhibitor, led to dramatic clinical improvement in a young patient with severe COVID-19-associated cytokine 
release syndrome.
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BACKGROUND
Patients admitted with COVID-19 pneumonia are often old with many comorbidities. However, younger patients seem to primarily 
experience an exaggerated response of their immune system to COVID-19 pulmonary infection, and develop features of cytokine release 
syndrome (CRS), which may be life threatening [1, 2].
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Thus far, there is no proven antiviral therapy for COVID-19, but profound immunosuppression has recently been suggested as a treatment 
for COVID-19-associated CRS [3]. We describe a case of life-threatening CRS caused by COVID-19 infection with a favourable response to 
immunosuppressive therapy with tocilizumab (TCZ).  
CASE DESCRIPTION
A 26-year-old, previously healthy man was referred to our emergency department on 28 March with a 5-day history of fever, dyspnoea and 
cough. He walked into the emergency department independently, but within 1 hour needed an oxygen supply of 15 l/min on an OxyMask 
to maintain his oxygen saturation at 90%. A pulmonary CT scan showed extensive areas of ground-glass opacities and subtle consolidations 
bilaterally, predominantly in the basal lung areas, with some extension to all pulmonary lobes (CO-RADS 5). A SARS-Corona E-swab PCR 
test returned a positive result within a few hours. Laboratory testing showed increased levels of C-reactive protein (CRP; 153 µg/ml), 
ferritin (703 ng/ml) and D-dimer (3233 ng/ml). The diagnosis of COVID-19 pneumonia was made and treatment with chloroquine and 
prophylactic ceftriaxone and low-molecular weight heparin was initiated.
The patient was admitted to the intensive care unit for treatment with high-flow oxygen (Optiflow, 30 l; 65% FiO2) resulting in a maximum 
O2 saturation of 93% and an arterial pO2 of 61.5 mmHg. On the second day of admission, the patient’s respiratory condition further 
deteriorated and he had to be intubated for invasive ventilation in the prone position. As the extreme clinical deterioration in conjunction 
with laboratory findings (Fig. 1) raised a high suspicion of CRS, we decided to administer a single intravenous dose of TCZ at a dose of 8 
mg/kg body-weight. TCZ is an IL-6-receptor-blocking biological drug commonly used in the treatment of autoimmune disorders such as 
rheumatoid arthritis. 
Figure 1. Laboratory findings. (left panel, A) C-reactive protein (CRP) and D-dimer; (right panel, B) IL-6 and ferritin levels. TCZ, tocilizumab
Initially, CRP, ferritin, D-dimer and IL-6 levels showed a further increase, suggestive of advancing CRS. However, from 31 March onwards 
(2 days after TCZ administration), ventilation conditions improved day-by-day. This was associated with a reversal of laboratory parameters 
toward normal levels of CRP, ferritin and IL-6 within 5 days of administration of TCZ. During this period, the patient was weaned from 
mechanical ventilation and successfully extubated. A chest x-ray performed on 5 April, 7 days after treatment with TCZ, showed complete 
resolution of abnormalities (Fig. 2). On 7 April, 9 days after treatment with TCZ, the patient was discharged from hospital without any need 
for supplemental oxygen. 
DISCUSSION
IL-6 plays a key role in the pathogenesis of CRS, although its contribution has not yet been fully elucidated. TCZ, a biological drug that 
binds to the IL-6 receptor and prevents IL-6 from signalling, is used successfully in the treatment of autoimmune diseases. It has also been 
approved for the treatment of severe or life-threatening CRS associated with chimeric antigen receptor (CAR) T-cell immunotherapy in 
patients with malignancy [4, 5].
Our case strongly suggests that administration of a single dose of TCZ in advancing SARS-CoV-2-induced CRS (within a hypothesized 
window of opportunity) contributes to a surprising turnaround in an otherwise damaging clinical course. 
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Figure 2. Chest x-ray on day 1 (left) 
of tocilizumab therapy compared 
with day 7 (right)
We cannot disregard the possibility that the patient’s recovery was spontaneous and that the association with TCZ was coincidental. 
However, spontaneous recovery seems highly unlikely here, and is in distinct contrast to our recent clinical experience in similar patients. 
Patients with a similar catastrophic course often died or needed prolonged mechanical ventilation with uncertain outcome.
The rapid clinical and biochemical improvement following TCZ administration suggests that treatment with immunotherapy can be crucial 
and life-saving in selected patients with COVID-19-induced CRS. Ongoing clinical trials with TCZ will hopefully produce rapid results.  
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